{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(1)"],"submitter":["Wang L"],"pubmed_abstract":["Clinical application of autologous chimeric antigen receptor (CAR)-T cells is complicated by limited targeting of cancer types, as well as the time-consuming and costly manufacturing process. We develop CD70-targeted, induced pluripotent stem cell-derived CAR-natural killer (NK) (70CAR-iNK) cells as an approach for universal immune cell therapy. Besides the CD70-targeted CAR molecule, 70CAR-iNK cells are modified with CD70 gene knockout, a high-affinity non-cleavable CD16 (hnCD16), and an interleukin (IL)-15 receptor α/IL-15 fusion protein (IL15RF). Multi-gene-edited 70CAR-iNK cells exhibit robust cytotoxicity against a wide range of tumors. In vivo xenograft models further demonstrate their potency in effectively targeting lymphoma and renal cancers. Furthermore, we find that recipient al"],"journal":["Cell reports. Medicine"],"pagination":["101889"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11866492"],"repository":["biostudies-literature"],"pubmed_title":["CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells."],"pmcid":["PMC11866492"],"pubmed_authors":["Shen L","Hu Y","Liang X","Wang D","Huang H","Mo G","Wang K","Wang L","Zhang P","Zhao M","Shao Y","Mo Z","Jia X","Wang Y","Song X","Zhou L","Chen N","Xu M","Yang L","Feng Y","Zhou Y","Zeng W","He X","Hu K","Yue Y","Hong R"],"additional_accession":[]},"is_claimable":false,"name":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells.","description":"Clinical application of autologous chimeric antigen receptor (CAR)-T cells is complicated by limited targeting of cancer types, as well as the time-consuming and costly manufacturing process. We develop CD70-targeted, induced pluripotent stem cell-derived CAR-natural killer (NK) (70CAR-iNK) cells as an approach for universal immune cell therapy. Besides the CD70-targeted CAR molecule, 70CAR-iNK cells are modified with CD70 gene knockout, a high-affinity non-cleavable CD16 (hnCD16), and an interleukin (IL)-15 receptor α/IL-15 fusion protein (IL15RF). Multi-gene-edited 70CAR-iNK cells exhibit robust cytotoxicity against a wide range of tumors. In vivo xenograft models further demonstrate their potency in effectively targeting lymphoma and renal cancers. Furthermore, we find that recipient al","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-02T18:15:54.253Z","creation":"2025-04-04T00:06:18.136Z"},"accession":"S-EPMC11866492","cross_references":{"pubmed":["39793572"],"doi":["10.1016/j.xcrm.2024.101889"]}}